GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiMed Biologics Inc (ROCO:4147) » Definitions » Change In Receivables

TaiMed Biologics (ROCO:4147) Change In Receivables : NT$-6.8 Mil (TTM As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is TaiMed Biologics Change In Receivables?

TaiMed Biologics's change in receivables for the quarter that ended in Mar. 2024 was NT$-16.2 Mil. It means TaiMed Biologics's Accounts Receivable increased by NT$16.2 Mil from Dec. 2023 to Mar. 2024 .

TaiMed Biologics's change in receivables for the fiscal year that ended in Dec. 2023 was NT$-62.6 Mil. It means TaiMed Biologics's Accounts Receivable increased by NT$62.6 Mil from Dec. 2022 to Dec. 2023 .

TaiMed Biologics's Accounts Receivable for the quarter that ended in Mar. 2024 was NT$151.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. TaiMed Biologics's Days Sales Outstanding for the three months ended in Mar. 2024 was 77.01.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. TaiMed Biologics's liquidation value for the three months ended in Mar. 2024 was NT$1,760.7 Mil.


TaiMed Biologics Change In Receivables Historical Data

The historical data trend for TaiMed Biologics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiMed Biologics Change In Receivables Chart

TaiMed Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -111.85 -43.03 86.07 72.30 -62.59

TaiMed Biologics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -72.08 49.14 -59.50 19.84 -16.24

TaiMed Biologics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-6.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TaiMed Biologics  (ROCO:4147) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

TaiMed Biologics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=151.032/178.948*91
=77.01

2. In Ben Graham's calculation of liquidation value, TaiMed Biologics's accounts receivable are only considered to be worth 75% of book value:

TaiMed Biologics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=2317.089-1276.755+0.75 * 151.032+0.5 * 1214.104
=1,760.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TaiMed Biologics Change In Receivables Related Terms

Thank you for viewing the detailed overview of TaiMed Biologics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


TaiMed Biologics (ROCO:4147) Business Description

Traded in Other Exchanges
N/A
Address
No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a Taiwan-based biotechnology company. It is engaged in the discovery, development, and delivery of medicines for infectious disease. It capitalizes on its intellectual, extensive expertise, and management resources to develop a health-care product pipeline that benefits patients, rewards investors, and propels to prominence in the biotechnology industry. The company's products pipeline includes TMB-365, VRC07-523LS, and others.

TaiMed Biologics (ROCO:4147) Headlines

No Headlines